论文部分内容阅读
背景与目的:胶质瘤是最常见的原发性恶性脑肿瘤,预后差,生存率低。近年来,以利用癌睾丸(cancer-testis,CT)抗原作为靶抗原行肿瘤免疫治疗已成为研究的热点,而OY-TES-1是CT抗原家族中的一员。本研究拟了解OY-TES-1在脑胶质瘤中的mRNA表达及其抗体出现情况,探讨将OY-TES-1应用于肿瘤免疫治疗及辅助诊断的可能性。方法:收集51例脑胶质瘤患者肿瘤组织标本及配套血清,107例健康人血清。通过RT-PCR,从mRNA水平研究OY-TES-1在脑胶质瘤组织中的表达;用酶联免疫吸附分析技术(enzyme linkedimmunosorbent assay,ELISA)检测患者及健康人血清OY-TES-1抗体;同时对OY-TES-1 mRNA的表达及血清抗体出现的临床意义做初步分析。结果:在脑胶质瘤患者中OY-TES-1 mRNA阳性率为80.4%(41/51),血清OY-TES-1抗体阳性率为15.7%(8/51),健康人血清则为阴性。OY-TES-1 mRNA的表达和血清抗体的出现均与脑胶质瘤患者的年龄、性别、病理分级、肿瘤大小等临床指标无关。结论:OY-TES-1在脑胶质瘤中存在较高的表达,并能引起部分患者的体液免疫反应,有望作为胶质瘤免疫治疗的靶抗原。
Background and Objective: Glioma is the most common primary malignant brain tumor with poor prognosis and low survival rate. In recent years, tumor immunotherapy using cancer-testis (CT) antigen as a target antigen has become a research hotspot, and OY-TES-1 is a member of the CT antigen family. This study intends to understand OY-TES-1 mRNA expression in brain gliomas and the appearance of its antibodies to explore the possibility of using OY-TES-1 for tumor immunotherapy and adjuvant diagnosis. Methods: Tumor samples of 51 glioma patients and their matched serums and 107 healthy volunteers were collected. The expression of OY-TES-1 in glioma tissues was detected by RT-PCR from mRNA level. The levels of serum OY-TES-1 antibody in patients and healthy individuals were detected by enzyme linked immunosorbent assay (ELISA) At the same time, the expression of OY-TES-1 mRNA and the clinical significance of serum antibody were analyzed. Results: The positive rate of OY-TES-1 mRNA in glioma patients was 80.4% (41/51), the positive rate of serum OY-TES-1 antibody was 15.7% (8/51), and the serum of healthy volunteers was negative . The expression of OY-TES-1 mRNA and the appearance of serum antibodies were all unrelated to clinical indicators such as age, sex, pathological grade and tumor size in glioma patients. CONCLUSION: OY-TES-1 is highly expressed in gliomas and can induce humoral immune responses in some patients and is expected to be the target antigen for glioma immunotherapy.